Johnson & Johnson Q2 2026: Strong Earnings, R&D Boost, and Steady Outlook
Johnson & Johnson Q2 2026 earnings: steady revenue, higher EPS, $5.4 B R&D, new oncology and cardio trials, and a robust cash‑flow outlook.
4 minutes to read
Dr. Sarah Winters
Medical Affairs Correspondent
Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.
AI Author, more information here
Merck Stays Core Dividend Asset in Schwab’s Income-Driven ETF
Merck & Co. (MRK) remains a core dividend asset in SCHD, offering steady 3.2% yield, 12‑year payout growth, strong earnings, and a growing oncology pipeline—ideal for income‑seeking investors.
3 minutes to read
Johnson & Johnson Q2 2026: Strong Revenue, R&D Growth, & Shareholder Value Focus
Johnson & Johnson’s Q2 2026 results reveal steady revenue growth, a resilient R&D pipeline, robust cash flow, and a proactive supply‑chain strategy – promising value for investors, clinicians, and patients alike.
4 minutes to read
Medtronic Shares Surge as Healthcare Outpaces Tech in Market Rotation
Medtronic PLC’s shares surge as investors shift toward defensive healthcare stocks, highlighting the company’s solid growth and the market’s pivot away from tech overvaluation.
2 minutes to read
Intuitive Surgical Shares Rise: Robust Safety, Efficacy & Resilient Market Performance
Intuitive Surgical’s July 2 gain highlights robotic‑surgery’s proven safety, faster recoveries, and cost savings—fueling investor confidence and clinical adoption.
3 minutes to read
Tech Sector Slows: Sartorius AG Shares Dip Despite Mild Market Gains
Investors see Sartorius AG’s shares slip amid muted tech‑sector volatility, yet fundamentals stay steady—watch for future momentum shifts.
2 minutes to read
Johnson & Johnson Q2 2024 Results: Steady Growth, Strong R&D, & 5% Profit Margin Goal
Johnson & Johnson posts steady Q2 earnings, strong consumer‑health growth, and new drug‑stent innovation—boosting patient care and shareholder value.
5 minutes to read
How Cigna Group’s 2025‑26 Annual Report Drives Wealth‑Management Growth via Digital & GCC Expansion
Explore The Cigna Group’s 2025‑26 Annual Report: how the firm is boosting recurring revenue, expanding in India’s Tier‑II/III markets and the GCC, and leveraging a digital, distribution‑led wealth‑management model for sustainable growth.
3 minutes to read
Insulet Corp Directors Convert Deferred Units to Shares, Boosting Insider Ownership
Insulet Corp’s directors boost ownership through deferred‑stock conversions, reinforcing alignment with shareholders while staying fully compliant with SEC Form 4 filings.
3 minutes to read
How Bayer’s New U.S. Subsidiary Ruveon Aims to Streamline Glyphosate Operations and Reduce Legal Risk
Ruveon, Bayer’s new U.S. subsidiary, streamlines glyphosate operations and legal defense after a Supreme Court ruling, boosting compliance, efficiency, and investor confidence.
4 minutes to read